Works matching IS 11738804 AND DT 2024 AND VI 38 AND IP 1

Results: 11

Acknowledgement to Referees.

Published in:: BioDrugs, 2024, v. 38, n. 1, p. 1, doi. 10.1007/s40259-023-00638-x
Publication type:: Article

Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries.

Published in:

BioDrugs, 2024, v. 38, n. 1, p. 133, doi. 10.1007/s40259-023-00636-z

By:

Woo, Hyunjung;
Shin, Gyeongseon;
Lee, Donghwan;
Kwon, Hye-Young;
Bae, SeungJin

Publication type:

Article

Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?

Published in:

BioDrugs, 2024, v. 38, n. 1, p. 61, doi. 10.1007/s40259-023-00634-1

By:

Avci, Ali Berkant;
Feist, Eugen;
Burmester, Gerd R.

Publication type:

Article

Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease.

Published in:

BioDrugs, 2024, v. 38, n. 1, p. 5, doi. 10.1007/s40259-023-00633-2

By:

Cummings, Jeffrey;
Osse, Amanda M. Leisgang;
Cammann, Davis;
Powell, Jayde;
Chen, Jingchun

Publication type:

Article

Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review.

Published in:

BioDrugs, 2024, v. 38, n. 1, p. 95, doi. 10.1007/s40259-023-00632-3

By:

Szwec, Sylwia;
Kapłucha, Zuzanna;
Chamberlain, Jeffrey S.;
Konieczny, Patryk

Publication type:

Article

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.

Published in:

BioDrugs, 2024, v. 38, n. 1, p. 121, doi. 10.1007/s40259-023-00630-5

By:

Papp, Kim A.;
Lebwohl, Mark G.;
Thaçi, Diamant;
Jaworski, Janusz;
Kwiek, Bartlomiej;
Trefler, Jakub;
Dudek, Anna;
Szepietowski, Jacek C.;
Reznichenko, Nataliya;
Narbutt, Joanna;
Baran, Wojciech;
Kolinek, Joanna;
Daniluk, Stefan;
Bartnicka-Maslowska, Katarzyna;
Reich, Adam;
Andrashko, Yuriy;
Kim, Sunghyun;
Bae, Yunju;
Jeon, Dabee;
Jung, Jinsun

Publication type:

Article

Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis.

Published in:

BioDrugs, 2024, v. 38, n. 1, p. 157, doi. 10.1007/s40259-023-00628-z

By:

Rui, Mingjun;
Wang, Yingcheng;
Li, Yunfei;
Fei, Zhengyang

Publication type:

Article

Outer Membrane Vesicle Vaccine Platforms.

Published in:

BioDrugs, 2024, v. 38, n. 1, p. 47, doi. 10.1007/s40259-023-00627-0

By:

Micoli, Francesca;
Adamo, Roberto;
Nakakana, Usman

Publication type:

Article

Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access.

Published in:

BioDrugs, 2024, v. 38, n. 1, p. 23, doi. 10.1007/s40259-023-00626-1

By:

Bittner, Beate;
Schmidt, Johannes

Publication type:

Article

Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.

Published in:

BioDrugs, 2024, v. 38, n. 1, p. 145, doi. 10.1007/s40259-023-00625-2

By:

Xue, Yu;
Hu, Jiankang;
Liu, Dongzhou;
Li, Jingyang;
Wu, Huaxiang;
Tan, Chunyu;
Dai, Lie;
Sun, Lingyun;
Li, Zhijun;
Xiao, Zhengyu;
Huang, Cibo;
Yan, Yan;
Ji, Fei;
Chen, Rong;
Zou, Hejian

Publication type:

Article

AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies.

Published in:

BioDrugs, 2024, v. 38, n. 1, p. 73, doi. 10.1007/s40259-023-00629-y

By:

Castro, Brenda F. M.;
Steel, Jason C.;
Layton, Christopher J.

Publication type:

Article